Market research
BXP.LSE Beximco Pharmaceuticals Limited
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 260M
- P/E ratio
- 5.31
- Analyst target
- 148
- Dividend yield
- Not available
- Beta
- 0.06
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 260M
- P/E ratio
- 5.31
- Analyst target
- 148
- Dividend yield
- Not available
- Beta
- 0.06
About
About Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals PLC. was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BXP.LSE discussion.
5 years, 5 months ago
Beximco Pharmaceuticals Limited is currently in a long term downtrend where the price is trading 0.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Beximco Pharmaceuticals Limited's total revenue rose by 20.7% to $7B since the same quarter in the previous year.
Its net income has increased by 31.6% to $1B since the same quarter in the previous year.
Finally, its free cash flow fell by 18.4% to $671M since the same quarter in the previous year.
Based on the above factors, Beximco Pharmaceuticals Limited gets an overall score of 3/5.